|
ARIAD Announces Election of Mary Tanner, Senior Bear Stearns Investment Banker, to Its Board Of Directors ARIAD Announces Election of Mary Tanner, Senior Bear Stearns Investment Banker, to Its Board Of Directors BW5130 SEP 22,2003 4:30 PACIFIC 07:30 EASTERN ( BW)(MA-ARIAD-PHARMACEUTICALS)(ARIA) ARIAD Announces Election of MaryTanner, Senior Bear Stearns Investment Banker, to Its Board OfDirectors Business Editors/Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 22, 2003--ARIADPharmaceuticals, Inc. (Nasdaq: ARIA) today announced the election ofMary Tanner, senior managing director at Bear Stearns & Co. Inc. andformer managing director and head of the healthcare practice at LehmanBrothers, Inc., to its Board of Directors. During her twenty-five yeartenure on Wall Street, Ms. Tanner has worked on or supervised morethan 550 transactions with a total value of over $175 billion,including ten large pharmaceutical mergers. At Lehman, Ms. Tannerbecame the first woman partner of the firm. Ms. Tanner received herB.A. from Harvard University. "Ms. Tanner´s record of achievement and leadership are widelyrecognized in both the investment banking and pharmaceuticalindustries. Her breadth of experience and network of relationshipswill be invaluable to us as we make the strategic decisions thatshould lead ARIAD to becoming a profitable commercial enterprise,"said Harvey J. Berger, M.D., chairman and chief executive officer ofARIAD. ARIAD is engaged in the discovery and development of breakthroughmedicines that regulate cell signaling with small molecules. TheCompany is developing a comprehensive approach to the treatment ofcancer and is primarily focused on a series of product candidates fortargeted oncology indications. ARIAD also has an exclusive license topioneering technology and patents related to the discovery,development and use of drugs that regulate NF-(kappa)kB cell-signalingactivity, which has been implicated in many major diseases. Additional information about ARIAD can be found on the web athttp://www.ariad.com. Some of the matters discussed herein are "forward-lookingstatements" within the meaning of the Private Securities LitigationReform Act of 1995. Such statements are identified by the use of wordssuch as "anticipate," "estimate," "expect," "project," "intend,""plan," "believe," and other words and terms of similar meaning inconnection with any discussion of future operating or financialperformance. Such statements are based on management´s currentexpectations and are subject to certain factors, risks anduncertainties that may cause actual results, outcome of events, timingand performance to differ materially from those expressed or impliedby such forward-looking statements. These risks include, but are notlimited to, risks and uncertainties regarding the Company´s ability toconduct preclinical and clinical studies of its product candidates andthe results of such studies, regulatory oversight, intellectualproperty claims, the timing, scope, cost and outcome of legalproceedings, future capital needs, key employees, dependence on theCompany´s collaborators and manufacturers, markets, economicconditions, products, services, prices, reimbursement rates,competition and other risks detailed in the Company´s public filingswith the Securities and Exchange Commission, including ARIAD´s AnnualReport on Form 10-K for the fiscal year ended December 31, 2002. Theinformation contained in this document is believed to be current as ofthe date of original issue. The Company does not intend to update anyof the forward-looking statements after the date of this document toconform these statements to actual results or to changes in theCompany´s expectations, except as required by law. --30--JK/bo* CONTACT: ARIAD Pharmaceuticals, Inc. Tom Pearson, 610-407-9260 or Kathy Lawton, 617-621-2345 KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: BANKING PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENTCHANGES SOURCE: ARIAD Pharmaceuticals, Inc. (c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission. |
|
| aus der Diskussion: | Konsolidierung abgeschlossen !! |
| Autor (Datum des Eintrages): | karljschmitt (22.09.03 14:59:07) |
| Beitrag: | 8 von 10 (ID:10805407) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |